Nadolol in hypertensive patients maintained on long-term hemodialysis.
The pharmacokinetics, efficacy, and safety of nadolol were evaluated in hypertensive patients maintained on long-term hemodialysis. In nine patients the plasma elimination half-life of unchanged nadolol averaged 26 hours following a single 40 mg oral dose during the interdialytic period. Nineteen patients received nadolol once after each dialysis session. In addition, 12 of the 19 patients also received hydralazine and/or furosemide daily. Predialysis blood pressures and heart rates were significantly lower with nadolol than with combination or single therapy with conventional antihypertensive drugs, including other beta blockers. Nadolol administered only after each dialysis session (i.e., two or three times a week), in conjunction with hydralazine and/or furosemide, is an effective antihypertensive agent in hypertensive patients receiving long-term hemodialysis.
D000319:Adrenergic beta-Antagonists / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000628:therapy; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D011412:Propanolamines / Q000097:blood / Q000627:therapeutic use*; D006435:Renal Dialysis; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D006830:Hydralazine; D009248:Nadolol; D005665:Furosemide